We develop proprietary drugs designed to offer significant improvements to patients and physicians. Our expertise consists of developing new drugs and guiding these through various regulatory and development pathways in preparation for their eventual commercialization. We generally focus our drug development efforts around disorders of the nervous system, such as chronic pain, with a primary focus on developing opioid formulations designed to reduce the potential risks of abuse or unintended use.
Our lead candidate is called Remoxy® ER, a proprietary oral formulation of oxycodone. Remoxy ER is an investigational drug and is not authorized for marketing in the U.S. for any indication. Pain Therapeutics, Inc. owns worldwide commercial rights to Remoxy ER.
Note: Our drug candidates are investigational drugs not approved by FDA and are not authorized for marketing in the U.S. for any indication.
COPYRIGHT © 2002-2016 / PAIN THERAPEUTICS, INC. / ALL RIGHTS RESERVED / 7801 N CAPITAL OF TEXAS HWY SUITE 260 / AUSTIN, TX 78731 / PHONE: 512-501-2444 / FAX: 512-501-0414